AstraZeneca Covid-19 Vaccine Trial Participant Reportedly Dies
Oct 23 2020
AstraZeneca's Oxford Covid-19 vaccine accurately follows the genetic instructions programmed into it by its developers to successfully provoke a strong immune response, according to a detailed analysis carried out by independent United Kingdom scientists. Soon after, the trials were restarted most everywhere, though not in the U.S.as of yet.
Oxford, too, confirmed the plan to keep testing, saying that after careful assessment there were no concerns about safety of the clinical trial.
The Federal University of Sao Paulo, which is helping coordinate phase 3 clinical trials in Brazil, said an independent review committee had also recommended their trial continue.
"Emergency use authorization will be granted to a vaccine that shows a very good safety profile and efficacy at or around 60% better than placebo, but I don't think the vaccine trials right now are being run very scientifically", said Jared Holz, healthcare strategist for brokerage Jefferies.
Doshi, an assistant professor of pharmaceutical health services research at the University of Maryland School of Pharmacy, said: "None of the trials now underway are created to detect a reduction in any serious outcome such as hospitalisations, intensive care use, or deaths".
The British-Swedish pharma multinational is conducting a stage three trial of its Covid-19 vaccine in partnership with Oxford. The ministry continues to work with companies to ensure proper vaccine trials are taking place in Japan, he said.
AstraZeneca shares turned negative and were down 1.7 percent.
The U.K.'s Medicines and Healthcare products Regulatory Agency determined that the evidence was insufficient to link AstraZeneca's U.K trial program setback with the vaccine, as per Reuters.
The country has the second most coronavirus-related fatalities in the world, and has reported over 5.2 million cases of the virus.
In September, the AstraZeneca vaccine trials were put on pause worldwide, after it was revealed that neurological illnesses were reported among some of the participants.